Scancell Holdings Plc · LSE:SCLP
Scancell — H1 FY2025 Earnings Presentation
27 slides from Scancell's earnings presentation, January 2025
Slide 1: FY25 Interim Results: Products, People and Progress
FY25 Interim Results Products, People and Progress P H I L L’ H U I L L I E R C E O SATH NI RMA L ANA NTHA N CFO JANUARY 2025
Slide 2: Company Snapshot
Company Snapshot Two differentiated products in clinical development in markets with major unmet needs. • Impressive efficacy, with long-term immune control of tumours and good safety profile Research and development supported by deep cancer immunology & translational medicine expertise Leadership t
Slide 3: Key Highlights
Key Highlights CLINICALLY VALIDATED VACCINES, COMMERCIALLY VALIDATED ANTIBODIES IND READY COMMERCIALLY VIABLE SCIB1 43 PATIENT PRODUCT FOR RANDOMISED STUDY 25-WEEK ORR DATA EXPECTED IN H1 2025 STRATEGIC PARTNERSHIP FOR NEEDLE FREE DELIVERY Pharma SCCHN 43% ORR** **CPI CONTROL 19% MODIFY EARLY CLINIC
Slide 4: Experienced Leadership Team Bolstered with Industry-Expertise now set for Execution
Experienced Leadership Team Bolstered with Industry-Expertise now set for Execution Professor Lindy Phil L’Huillier Nermeen Durrant Chief Executive Chief Scientific Varawalla Officer Chief Medical Officer Officer & Founder Sath Mandeep Sehmi Callum Scott Nirmalananthan Head of Chief Financial Head o
Slide 5: Lead Vaccine Products in Advanced Melanoma
Lead Vaccine Products in Advanced Melanoma JANUARY 25 CONFIDENTIAL 5
Slide 6: Differentiated Vaccine Products Across Multiple Indications
Differentiated Vaccine Products Across Multiple Indications UN LO C KI N G P OT EN T I AL FO R N O N - P ER S O N AL I S ED C USTO M I S AB L E VACC I N ES F RO M T H E I M M U N O B O DY ® P L AT F O R M DUAL ACTING, PATIENT CONVENIENT CUSTOMISABLE OFF THE EXCELLENT SAFETY APC TARGETED SHELF NEEDLE
Slide 7: SCIB1/iSCIB1+ Aims to Improve on 5-year Survival of Advanced Melanoma Patients
SCIB1/iSCIB1+ Aims to Improve on 5-year Survival of Advanced Melanoma Patients • Scancell SCIB vaccine works synergistically with standard of care KEY FACTS checkpoint inhibitors (CPI) • Global annual incidence of 320,000 patients, ~58,000 deaths per year • CPIs open up immune access to the tumour,
Slide 8: Market Opportunity in Melanoma substantial
Market Opportunity in Melanoma substantial ADDRESSABLE SCIB1 PATIENT iSCIB1+ ~$1bn1 market size ~$3.8bn1 market size POPULATION iSCIB1+ second generation vaccine offering: Unresectable Melanoma • Improved product allowing 100% ~38,000 patients access to the addressable patient SCIB1 is being develop
Slide 9: SCOPE Study Design (138 patients)
SCOPE Study Design (138 patients) Eligibility Four Cohorts (16 sites) Endpoints Unresectable stage III or IV melanoma SCIB1 + SoC nivolumab & ipilimumab (n=43) Primary Endpoints Frontline patients SCIB1 + SoC pembrolizumab (n=9) ORR Suitable for treatment with ipilimumab and iSCIB1+ In
Slide 10: Strong tumour reduction, superior to historic controls
Strong tumour reduction, superior to historic controls giving potential marked improvement of patients 2 5 PAT I E N T S AT 2 5 W E E KS D E M O N ST R AT I N G 7 2 % O R R AT 6 M O N T H S JANUARY 25 10
Slide 11: Progression free survival, superior to historic controls
Progression free survival, superior to historic controls giving potential for long term immune control of tumours 2 5 PAT I E N T S AT 2 5 W E E KS D E M O N ST R AT I N G 8 0 % P F S AT 6 M O N T H S SCOPE: Progression-Free Survival Cohort 1 (n=25) SCIB1+Ipi-Nivo Ongoing patients have been censored
Slide 12: SCIB1 has Previously Demonstrated Efficacy as a Monotherapy
SCIB1 has Previously Demonstrated Efficacy as a Monotherapy • SCIB1 has previously demonstrated efficacy as a monotherapy post resection • 88% of patients disease-free for 5+ years JANUARY 25 12
Slide 13: Superiority to Current Therapies Strongly Demonstrated
Superiority to Current Therapies Strongly Demonstrated SCOPE Cohort 1 Real World N=25 Outcomes with • Compelling efficacy data, double checkpoints1 outperforming current SoC benchmarks Disease Control Rate (DCR) 84% 58% • Improved durability of Objective Response Rate (ORR) 72% 48% response Complete
Slide 14: Status and Next Steps for our Lead Product
Status and Next Steps for our Lead Product • SCIB1 cohort now fully recruited with 43 patients and 25-week ORR data expected in H1 2025 • iSCIB1+, a next generation vaccine recruiting well, with 25-week ORR data expected mid-year • Intradermal (ID) cohort with iSCIB1+ added to the SCOPE study. Indus
Slide 15: Modi-1, our second product for Head & Neck and Renal Cancers
Modi-1, our second product for Head & Neck and Renal Cancers JANUARY 25 15
Slide 16: Moditope Vaccine Platform
Moditope® Vaccine Platform TARGETING STRESS INDUCED POST TRANSLATIONAL MODIFICATIONS TUMOUR PAN OFF THE LOW NEOANTIGEN CUSTOMISABLE TUMOUR SHELF TOXICITY VACCINE • Modi-1 targets citrullinated peptides, tumour-specific neoantigens generated from stress-induced post translational modifications (siPTM
Slide 17: Modi-1 – Addressing Multiple Advanced Solid Tumours with Poor Treatment Outcomes
Modi-1 – Addressing Multiple Advanced Solid Tumours with Poor Treatment Outcomes MARKET OPPORTUNITY SCCHN is the 9th most common malignant tumor, representing 6% of all cancer cases Renal Cell Cancer is the eighth most common cancer in the United States Anticipated to reach an annual incidence rate
Slide 18: ModiFY Study Design
ModiFY Study Design Combination therapy Endpoints Primary Endpoints Combination with anti-PD1 in Head and Neck cancer • ORR showing clinical responses at Simon Stage 1 Secondary Endpoints • DoR • PFS Combination with doublet CPI therapy in Renal cancer • OS • Modi-1, a citrullinated peptide off the
Slide 19: Modi-1 shows non-futility in HPV negative Head and Neck Squamous Cell Carcinoma
Modi-1 Moditope® shows non-futility in HPV negative Head and Neck Squamous Cell Carcinoma (HNSCC) • Study designed to determine if the overall objective response rate (ORR) in patients could be improved by combining Modi-1 Moditope® in combination with standard of care single agent checkpoint inhibi
Slide 20: GlyMabs - Unique antibodies targeting Glycans
GlyMabs® - Unique antibodies targeting Glycans JANUARY 25 20
Slide 21: GlyMab Antibody Platform
GlyMab® Antibody Platform S U P E R S P EC I F I C T U M O U R TA RG E TS TARGETS TUMOUR HIGH AFFINTY AND CLINICALLY VALIDATED GROWING MULTIPLE THERAPEUTIC ASSOCIATED GLYCANS SPECIFICITY TARGETS PIPELINE FORMATS “A key challenge targeting this high potential class is generating antibodies with high
Slide 22: Industry Validation Demonstrating Therapeutic Potential of GlyMabs
Industry Validation Demonstrating Therapeutic Potential of GlyMabs® STRONG COMMERCIAL INTEREST FOR LEAD ANTIBODY SC134 • Sialyl-di-Lewisa • SC129 licensed to Genmab in 2022. Potential SC129 • Pancreatic cancer milestones of up to $624m, plus royalties. Development progressing well • Fucosyl GM1 SC13
Slide 23: SC134 targeting FucGM1
SC134 targeting FucGM1 • Key attributes of target • FucosylGM1 glycolipid • Highly tumour-specific (>70% of SCLC tissues) Cancer glycan target • Normal human distribution • Clinically validated (BMS) • Competitive attributes • Monoclonal IgG1 Humanised antibody with patent protection. Patent granted
Slide 24: Financials & Outlook
Financials & Outlook S C A N C E L L .C O.U K
Slide 25: Scancell Key Financial Highlights
Scancell Key Financial Highlights For the 6 months ended 31st October 2024 Consolidated Statement of 6 months 6 months Comprehensive Income (£m) 31 October 2024 31 October 2023 ► Genmab exercised option for second antibody, SC2811, for $6m in upfront payment Revenue - - ► SC129, first out licenced a
Slide 26: Corporate & Development Milestones Achieved in 2024 and Anticipated in 2025
Corporate & Development Milestones Achieved in 2024 and Anticipated in 2025 P O S I T I O N E D TO AC C E L E R AT E C L I N I C A L D E V E LO P M E N T TO D E L I V E R E F F E CT I V E C A N C E R V A C C I N E T H E R A P I E S A N D D E V E L O P M E N T O F G LY M A B ® A N T I B O D I E S 202
Slide 27: Contact us
Contact us T +44 (0) 1865 582 066 W S C A N C E L L .C O.U K SCANCELL Unit 202 Bellhouse Building, Sanders Road, Oxford Science Park, Oxford OX4 4GD, UK